Journal
JOURNAL OF DERMATOLOGY
Volume 43, Issue 2, Pages 210-214Publisher
WILEY
DOI: 10.1111/1346-8138.13028
Keywords
Hashimoto disease; insulin-dependent diabetes; malignant melanoma; nivolumab; ultrasonography; vitiligo
Categories
Ask authors/readers for more resources
Nivolumab, a blockade of programmed cell death 1, is now administrated for advanced malignant melanomas. Nivolumab-associated adverse events include organ-specific autoimmune disorders; autoimmune thyroid disease, vitiligo and insulin-dependent diabetes. However, predisposed persons are currently unknown. Here, we report serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab: one with Hashimoto disease and another with probable subclinical Hashimoto disease. We should verify if nivolumab-related hypothyroidism and hyperthyroidism are predisposed to occur in euthyroid individuals with subclinical autoimmune thyroid disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available